Predictive Biomarkers of Response to Neoadjuvant Chemotherapy in Breast Cancer: Current and Future Perspectives for Precision Medicine
Pathological complete response (pCR) after neoadjuvant chemotherapy in patients with early breast cancer is correlated with better survival. Meanwhile, an expanding arsenal of post-neoadjuvant treatment strategies have proven beneficial in the absence of pCR, leading to an increased use of neoadjuva...
Saved in:
Published in | Cancers Vol. 14; no. 16; p. 3876 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Basel
MDPI AG
01.08.2022
MDPI |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Pathological complete response (pCR) after neoadjuvant chemotherapy in patients with early breast cancer is correlated with better survival. Meanwhile, an expanding arsenal of post-neoadjuvant treatment strategies have proven beneficial in the absence of pCR, leading to an increased use of neoadjuvant systemic therapy in patients with early breast cancer and the search for predictive biomarkers of response. The better prediction of response to neoadjuvant chemotherapy could enable the escalation or de-escalation of neoadjuvant treatment strategies, with the ultimate goal of improving the clinical management of early breast cancer. Clinico-pathological prognostic factors are currently used to estimate the potential benefit of neoadjuvant systemic treatment but are not accurate enough to allow for personalized response prediction. Other factors have recently been proposed but are not yet implementable in daily clinical practice or remain of limited utility due to the intertumoral heterogeneity of breast cancer. In this review, we describe the current knowledge about predictive factors for response to neoadjuvant chemotherapy in breast cancer patients and highlight the future perspectives that could lead to the better prediction of response, focusing on the current biomarkers used for clinical decision making and the different gene signatures that have recently been proposed for patient stratification and the prediction of response to therapies. We also discuss the intratumoral phenotypic heterogeneity in breast cancers as well as the emerging techniques and relevant pre-clinical models that could integrate this biological factor currently limiting the reliable prediction of response to neoadjuvant systemic therapy. |
---|---|
AbstractList | Pathological complete response (pCR) after neoadjuvant chemotherapy in patients with early breast cancer is correlated with better survival. Meanwhile, an expanding arsenal of post-neoadjuvant treatment strategies have proven beneficial in the absence of pCR, leading to an increased use of neoadjuvant systemic therapy in patients with early breast cancer and the search for predictive biomarkers of response. The better prediction of response to neoadjuvant chemotherapy could enable the escalation or de-escalation of neoadjuvant treatment strategies, with the ultimate goal of improving the clinical management of early breast cancer. Clinico-pathological prognostic factors are currently used to estimate the potential benefit of neoadjuvant systemic treatment but are not accurate enough to allow for personalized response prediction. Other factors have recently been proposed but are not yet implementable in daily clinical practice or remain of limited utility due to the intertumoral heterogeneity of breast cancer. In this review, we describe the current knowledge about predictive factors for response to neoadjuvant chemotherapy in breast cancer patients and highlight the future perspectives that could lead to the better prediction of response, focusing on the current biomarkers used for clinical decision making and the different gene signatures that have recently been proposed for patient stratification and the prediction of response to therapies. We also discuss the intratumoral phenotypic heterogeneity in breast cancers as well as the emerging techniques and relevant pre-clinical models that could integrate this biological factor currently limiting the reliable prediction of response to neoadjuvant systemic therapy. Simple SummaryDespite the increased use of neoadjuvant chemotherapy in the early setting of breast cancer, there is a clinical need for predictive markers of response in daily practice. In the era of precision medicine and personalized treatment, new predictive markers that enable the better selection of patients for specific therapies are required. In this review, we describe the current knowledge about the molecular biomarkers used for clinical decision making for patients with breast cancer. We also report how microenvironment-driven intratumoral heterogeneity may influence the validation of biomarkers useful for precision medicine. We provide an overview of promising biomarkers, including pathological markers, genetic signatures, radiological techniques and liquid biopsies, with a great potential to be implemented in routine clinical practice. Finally, we discuss the use of relevant pre-clinical models of breast cancer to integrate microenvironmental specificities in order to identify and validate reliable biomarkers of (non-)response to neoadjuvant chemotherapy.AbstractPathological complete response (pCR) after neoadjuvant chemotherapy in patients with early breast cancer is correlated with better survival. Meanwhile, an expanding arsenal of post-neoadjuvant treatment strategies have proven beneficial in the absence of pCR, leading to an increased use of neoadjuvant systemic therapy in patients with early breast cancer and the search for predictive biomarkers of response. The better prediction of response to neoadjuvant chemotherapy could enable the escalation or de-escalation of neoadjuvant treatment strategies, with the ultimate goal of improving the clinical management of early breast cancer. Clinico-pathological prognostic factors are currently used to estimate the potential benefit of neoadjuvant systemic treatment but are not accurate enough to allow for personalized response prediction. Other factors have recently been proposed but are not yet implementable in daily clinical practice or remain of limited utility due to the intertumoral heterogeneity of breast cancer. In this review, we describe the current knowledge about predictive factors for response to neoadjuvant chemotherapy in breast cancer patients and highlight the future perspectives that could lead to the better prediction of response, focusing on the current biomarkers used for clinical decision making and the different gene signatures that have recently been proposed for patient stratification and the prediction of response to therapies. We also discuss the intratumoral phenotypic heterogeneity in breast cancers as well as the emerging techniques and relevant pre-clinical models that could integrate this biological factor currently limiting the reliable prediction of response to neoadjuvant systemic therapy. Despite the increased use of neoadjuvant chemotherapy in the early setting of breast cancer, there is a clinical need for predictive markers of response in daily practice. In the era of precision medicine and personalized treatment, new predictive markers that enable the better selection of patients for specific therapies are required. In this review, we describe the current knowledge about the molecular biomarkers used for clinical decision making for patients with breast cancer. We also report how microenvironment-driven intratumoral heterogeneity may influence the validation of biomarkers useful for precision medicine. We provide an overview of promising biomarkers, including pathological markers, genetic signatures, radiological techniques and liquid biopsies, with a great potential to be implemented in routine clinical practice. Finally, we discuss the use of relevant pre-clinical models of breast cancer to integrate microenvironmental specificities in order to identify and validate reliable biomarkers of (non-)response to neoadjuvant chemotherapy. Pathological complete response (pCR) after neoadjuvant chemotherapy in patients with early breast cancer is correlated with better survival. Meanwhile, an expanding arsenal of post-neoadjuvant treatment strategies have proven beneficial in the absence of pCR, leading to an increased use of neoadjuvant systemic therapy in patients with early breast cancer and the search for predictive biomarkers of response. The better prediction of response to neoadjuvant chemotherapy could enable the escalation or de-escalation of neoadjuvant treatment strategies, with the ultimate goal of improving the clinical management of early breast cancer. Clinico-pathological prognostic factors are currently used to estimate the potential benefit of neoadjuvant systemic treatment but are not accurate enough to allow for personalized response prediction. Other factors have recently been proposed but are not yet implementable in daily clinical practice or remain of limited utility due to the intertumoral heterogeneity of breast cancer. In this review, we describe the current knowledge about predictive factors for response to neoadjuvant chemotherapy in breast cancer patients and highlight the future perspectives that could lead to the better prediction of response, focusing on the current biomarkers used for clinical decision making and the different gene signatures that have recently been proposed for patient stratification and the prediction of response to therapies. We also discuss the intratumoral phenotypic heterogeneity in breast cancers as well as the emerging techniques and relevant pre-clinical models that could integrate this biological factor currently limiting the reliable prediction of response to neoadjuvant systemic therapy. Despite the increased use of neoadjuvant chemotherapy in the early setting of breast cancer, there is a clinical need for predictive markers of response in daily practice. In the era of precision medicine and personalized treatment, new predictive markers that enable the better selection of patients for specific therapies are required. In this review, we describe the current knowledge about the molecular biomarkers used for clinical decision making for patients with breast cancer. We also report how microenvironment-driven intratumoral heterogeneity may influence the validation of biomarkers useful for precision medicine. We provide an overview of promising biomarkers, including pathological markers, genetic signatures, radiological techniques and liquid biopsies, with a great potential to be implemented in routine clinical practice. Finally, we discuss the use of relevant pre-clinical models of breast cancer to integrate microenvironmental specificities in order to identify and validate reliable biomarkers of (non-)response to neoadjuvant chemotherapy. |
Audience | Academic |
Author | Van Bockstal, Mieke R Berlière, Martine Fellah, Latifa Corbet, Cyril Gerday, Amandine Leconte, Isabelle Duhoux, Francois P Derouane, Françoise van Marcke, Cédric Galant, Christine |
AuthorAffiliation | 4 Department of Gynecology, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate 10, 1200 Brussels, Belgium 1 Department of Medical Oncology, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate 10, 1200 Brussels, Belgium 7 Department of Pathology, Cliniques Universitaires Saint-Luc, Avenue Hippocrate 10, 1200 Brussels, Belgium 3 Institut de Recherche Expérimentale et Clinique (IREC), Pole of Medical Imaging, Radiotherapy and Oncology (MIRO), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium 8 Institut de Recherche Expérimentale et Clinique (IREC), Pole of Pharmacology and Therapeutics (FATH), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium 2 Breast Clinic, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate 10, 1200 Brussels, Belgium 6 Department of Radiology, Cliniques Universitaires Saint-Luc, Avenue Hippocrate 10, 1200 Brussels, Belgium 5 Institut |
AuthorAffiliation_xml | – name: 5 Institut de Recherche Expérimentale et Clinique (IREC), Pole of Gynecology (GYNE), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium – name: 3 Institut de Recherche Expérimentale et Clinique (IREC), Pole of Medical Imaging, Radiotherapy and Oncology (MIRO), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium – name: 4 Department of Gynecology, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate 10, 1200 Brussels, Belgium – name: 8 Institut de Recherche Expérimentale et Clinique (IREC), Pole of Pharmacology and Therapeutics (FATH), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium – name: 2 Breast Clinic, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate 10, 1200 Brussels, Belgium – name: 7 Department of Pathology, Cliniques Universitaires Saint-Luc, Avenue Hippocrate 10, 1200 Brussels, Belgium – name: 1 Department of Medical Oncology, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate 10, 1200 Brussels, Belgium – name: 6 Department of Radiology, Cliniques Universitaires Saint-Luc, Avenue Hippocrate 10, 1200 Brussels, Belgium |
Author_xml | – sequence: 1 givenname: Françoise orcidid: 0000-0002-0199-1366 surname: Derouane fullname: Derouane, Françoise – sequence: 2 givenname: Cédric orcidid: 0000-0003-3454-0630 surname: van Marcke fullname: van Marcke, Cédric – sequence: 3 givenname: Martine surname: Berlière fullname: Berlière, Martine – sequence: 4 givenname: Amandine surname: Gerday fullname: Gerday, Amandine – sequence: 5 givenname: Latifa surname: Fellah fullname: Fellah, Latifa – sequence: 6 givenname: Isabelle surname: Leconte fullname: Leconte, Isabelle – sequence: 7 givenname: Mieke R. surname: Van Bockstal fullname: Van Bockstal, Mieke R. – sequence: 8 givenname: Christine surname: Galant fullname: Galant, Christine – sequence: 9 givenname: Cyril orcidid: 0000-0001-8795-9131 surname: Corbet fullname: Corbet, Cyril – sequence: 10 givenname: Francois P. orcidid: 0000-0002-5429-7888 surname: Duhoux fullname: Duhoux, Francois P. |
BookMark | eNptks9vFCEUx4mpsbX27JXEi5dtYRh-eTBpN7aaVG2MngkDb7qsszDCzCb9B_y7y7aN2kY4QB6f9_2-R95LtBdTBIReU3LMmCYnzkYHudCWCqakeIYOGiKbhRC63fvnvo-OSlmTuhijUsgXaJ8JQokS-gD9vsrgg5vCFvBZSBubf1ZJnHr8DcqYYgE8JfwFkvXreWvjhJcr2KRpBdmONzhEfJbBlhq-K-YdXs45Q8Vs9Ph8nuYM-KoqjnDnUXCfMq6eLpSQIv68Mw8RXqHnvR0KHD2ch-jH-Yfvy4-Ly68Xn5anlwvXCj4tKK9H0yqnveWceN9LxnjDOTCwvOuk7AT3ynddaxlXWoG2veYNKOE9UZIdovf3uuPcbcC7Wmm2gxlzqJ3fmGSDefwSw8pcp63RLeFatlXg7YNATr9mKJPZhOJgGGyENBfTSCJF_VvCK_rmCbpOc461vR0laMOlUn-pazuACbFP1dftRM2pbFqmWUNppY7_Q9XtYRNcHYs-1PijhJP7BJdTKRn6Pz1SYnbTY55MD7sFCUC6WA |
CitedBy_id | crossref_primary_10_3390_cancers15030597 crossref_primary_10_3390_cancers15245794 crossref_primary_10_3390_ijms24129984 crossref_primary_10_1007_s10549_024_07336_4 crossref_primary_10_1186_s13073_024_01286_8 crossref_primary_10_3390_ijms241411297 crossref_primary_10_1002_cam4_6955 crossref_primary_10_1186_s12905_024_03165_1 crossref_primary_10_1186_s13046_024_02998_w crossref_primary_10_3389_fonc_2023_1207948 crossref_primary_10_1038_s41416_024_02595_w crossref_primary_10_1093_jncics_pkad107 crossref_primary_10_3390_cancers15041032 crossref_primary_10_1186_s12885_023_10817_2 crossref_primary_10_1002_jmri_28476 crossref_primary_10_1186_s13000_024_01451_y crossref_primary_10_3390_ijerph20021617 crossref_primary_10_1007_s00432_023_04588_3 crossref_primary_10_1186_s13058_024_01788_8 |
Cites_doi | 10.1002/ijc.31070 10.1038/s41598-020-69026-7 10.1200/JCO.2009.23.7370 10.1093/annonc/mdu450 10.1038/nrclinonc.2017.74 10.1111/cge.13514 10.7150/jca.23367 10.1016/j.omto.2021.09.002 10.1200/JCO.19.00945 10.1007/s10549-018-5020-7 10.1007/s00439-021-02390-0 10.3322/caac.21660 10.3390/ijms22179644 10.1038/s41598-021-94184-7 10.1186/1471-2350-13-45 10.3892/or.2021.8089 10.1186/s40364-022-00356-6 10.1371/journal.pone.0236182 10.1056/NEJMoa2112651 10.1016/j.tranon.2021.101183 10.1038/sj.bjc.6605587 10.1200/GO.20.00575 10.3390/cancers13194910 10.1245/s10434-019-08039-7 10.3390/cancers12082012 10.1007/s10147-013-0614-x 10.1016/j.ejca.2017.07.041 10.1038/s41523-020-00197-2 10.18632/oncotarget.8862 10.1158/1078-0432.CCR-20-0073 10.1158/1078-0432.CCR-18-3190 10.1016/j.ejca.2020.04.020 10.1016/j.anndiagpath.2019.04.004 10.1007/s11523-021-00819-0 10.3390/cancers12051133 10.1200/JCO.2009.23.8451 10.1136/amiajnl-2012-001460 10.1155/2020/4736091 10.2217/fon-2016-0428 10.1038/s12276-020-0420-2 10.1097/PAP.0000000000000162 10.1038/s41698-021-00168-1 10.1158/1078-0432.CCR-21-3231 10.1126/scitranslmed.aax7392 10.1038/s41379-020-0544-x 10.1016/j.cell.2015.03.053 10.3389/fonc.2021.632357 10.1097/RLI.0000000000000518 10.1038/srep45733 10.1002/jmri.25279 10.1001/jamanetworkopen.2019.2561 10.1200/JCO.2014.58.1967 10.1200/JCO.2019.37.15_suppl.e12093 10.1097/MD.0000000000002453 10.1093/annonc/mdw610 10.1200/jco.2010.28.15_suppl.537 10.1097/MD.0000000000002914 10.1016/S1470-2045(14)70160-3 10.3390/ijms23031665 10.1016/j.annonc.2022.04.072 10.1158/1078-0432.CCR-13-2933 10.1007/s10549-018-4801-3 10.1016/j.molonc.2010.11.003 10.1056/NEJMoa1804710 10.1016/j.clbc.2019.05.014 10.1111/tbj.13032 10.1179/1973947812Y.0000000049 10.1038/s41379-021-00865-z 10.1007/s10549-009-0333-1 10.1016/j.tranon.2019.05.004 10.1038/s41419-017-0035-2 10.1016/j.ctrv.2017.04.005 10.1007/s10549-007-9590-z 10.1177/1178223420980377 10.1101/mcs.a003772 10.1038/s43018-022-00337-6 10.1158/1078-0432.CCR-04-2421 10.1016/S0140-6736(13)62422-8 10.1038/nrclinonc.2015.73 10.18632/oncotarget.1950 10.1093/annonc/mdz201 10.3389/fbioe.2021.662749 10.1016/j.annonc.2020.09.010 10.1016/j.tranon.2019.06.004 10.1038/s41416-021-01327-8 10.1007/s10549-013-2572-4 10.1073/pnas.191367098 10.1158/1078-0432.CCR-18-2521 10.1158/1078-0432.CCR-09-1532 10.1016/j.ejca.2012.05.023 10.1055/a-1124-7225 10.1038/s41416-021-01328-7 10.1245/s10434-018-07107-8 10.1200/JCO.2005.02.0818 10.1152/ajpcell.00120.2020 10.1016/j.breast.2009.03.005 10.1038/s41572-019-0111-2 10.1148/radiol.2017170180 10.1007/s10549-018-4990-9 10.1158/0008-5472.CAN-21-2807 10.1200/JCO.2015.62.1268 10.1016/j.annonc.2020.11.007 10.1007/s10549-020-05658-7 10.1200/JCO.2008.18.1370 10.1111/jcmm.15216 10.1152/ajpcell.00109.2021 10.1038/bjc.2011.159 10.1158/1078-0432.CCR-11-0926 10.1148/radiol.2017170143 10.1093/annonc/mdw262 10.3390/cancers13153813 10.3390/cancers13102356 10.1038/s41598-020-80037-2 10.1002/cam4.2281 10.1001/jamaoncol.2015.0830 10.3390/cancers12040958 10.1016/j.annonc.2020.08.2241 10.1016/j.clbc.2020.05.008 10.3233/BD-150199 10.1093/jnci/dji021 10.1371/journal.pone.0157368 10.1016/S1470-2045(15)00542-2 10.1016/j.canlet.2014.06.022 10.1016/j.canlet.2014.09.014 10.1245/s10434-021-10829-x 10.1016/j.cell.2017.11.010 10.1016/j.breast.2021.01.001 10.3390/cancers13215364 10.3390/jcm5020017 10.18632/oncotarget.27867 10.1002/bjs.4840 10.1186/s12938-021-00899-z 10.1016/j.anndiagpath.2020.151634 10.3747/co.25.3888 10.1038/35021093 10.1056/NEJMoa1910549 10.1200/JCO.2008.18.1024 10.1093/jnci/djy076 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9 10.1097/MD.0000000000013842 10.1172/JCI45014 10.1200/jco.2015.33.15_suppl.11049 10.1056/NEJMoa1602253 10.1093/jnci/djaa201 10.1016/S0140-6736(16)32454-0 10.1016/j.annonc.2020.01.072 10.1016/j.semcancer.2018.06.005 10.1016/j.esmoop.2021.100103 10.1200/JCO.2017.75.9175 10.3390/cancers14020310 10.1002/ame2.12077 10.1093/jnci/djn085 10.1016/S1470-2045(17)30904-X 10.1007/s10555-017-9684-y 10.1158/1078-0432.CCR-15-0630 10.1093/jnci/djy018 10.1007/s00259-020-04684-3 10.1007/s12149-018-1253-0 10.1038/s41598-021-94004-y 10.1093/annonc/mdz158 10.1007/s11307-018-1181-3 10.1158/2159-8290.CD-16-1154 10.1093/annonc/mdz173 10.1016/j.breast.2019.10.018 10.1158/1078-0432.CCR-21-2260 10.1016/j.ejca.2021.03.043 10.1016/j.omtn.2020.12.018 10.2217/fon-2016-0420 10.1245/s10434-019-07555-w 10.1093/annonc/mdv395 10.1200/JCO.2000.18.8.1689 10.3390/cancers12123869 10.1007/s10334-021-00941-0 10.3390/cancers12092497 10.1016/S0140-6736(20)31953-X 10.1038/s41416-020-0894-7 10.1007/s10549-019-05226-8 10.1038/s41467-018-06052-0 10.1007/s10549-010-1228-x 10.1200/JCO.2011.38.8595 10.3892/ol.2021.12809 10.2147/CMAR.S304547 10.1016/j.semcancer.2019.12.003 10.1038/s41416-021-01295-z 10.1373/clinchem.2016.262337 10.1016/j.semcancer.2021.07.010 10.18632/oncotarget.27742 10.1038/s41467-022-29358-6 10.1093/annonc/mdt494 10.1245/s10434-015-4404-8 10.1158/1078-0432.CCR-15-1603 10.1158/1078-0432.CCR-15-2338 10.18632/oncotarget.28002 10.5301/ijbm.5000291 10.3390/cancers13081964 10.1186/s12916-015-0540-z |
ContentType | Journal Article |
Copyright | COPYRIGHT 2022 MDPI AG 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2022 by the authors. 2022 |
Copyright_xml | – notice: COPYRIGHT 2022 MDPI AG – notice: 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2022 by the authors. 2022 |
DBID | AAYXX CITATION 3V. 7T5 7TO 7XB 8FE 8FH 8FK 8G5 ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO GNUQQ GUQSH H94 HCIFZ LK8 M2O M7P MBDVC PIMPY PQEST PQQKQ PQUKI PRINS Q9U 7X8 5PM |
DOI | 10.3390/cancers14163876 |
DatabaseName | CrossRef ProQuest Central (Corporate) Immunology Abstracts Oncogenes and Growth Factors Abstracts ProQuest Central (purchase pre-March 2016) ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials Biological Science Collection ProQuest Central ProQuest Natural Science Collection ProQuest One Community College ProQuest Central Korea ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts SciTech Premium Collection (Proquest) (PQ_SDU_P3) Biological Sciences ProQuest Research Library Biological Science Database Research Library (Corporate) Publicly Available Content (ProQuest) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef Publicly Available Content Database Research Library Prep ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest Central Essentials ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Central China ProQuest Central Natural Science Collection ProQuest Central Korea Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Biological Science Collection ProQuest Central Basic ProQuest One Academic Eastern Edition Biological Science Database ProQuest SciTech Collection ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database CrossRef |
Database_xml | – sequence: 1 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2072-6694 |
ExternalDocumentID | A724393211 10_3390_cancers14163876 |
GeographicLocations | Belgium |
GeographicLocations_xml | – name: Belgium |
GrantInformation_xml | – fundername: FSR grantid: 26.05.2020 – fundername: Fonds de Recherche Clinique – fundername: Fondation Belge contre le Cancer grantid: 2017-034 – fundername: Fondation Saint-Luc – fundername: Foundation Against Cancer grantid: 2019-089 |
GroupedDBID | --- 3V. 53G 5VS 8FE 8FH 8G5 AADQD AAFWJ AAYXX ABDBF ABUWG ADBBV AFKRA AFPKN AFZYC ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ CCPQU CITATION DIK DWQXO E3Z EBD ESX GNUQQ GROUPED_DOAJ GUQSH GX1 HCIFZ HYE IAO IHR ITC KQ8 LK8 M2O M48 M7P MODMG M~E OK1 P6G PGMZT PIMPY PQQKQ PROAC RIG RPM TUS 7T5 7TO 7XB 8FK H94 MBDVC PQEST PQUKI PRINS Q9U 7X8 5PM |
ID | FETCH-LOGICAL-c465t-15465248c9da550ddf7335255e3ea5bb77b65d8dbb4a35898e9af952e86dd0873 |
IEDL.DBID | RPM |
ISSN | 2072-6694 |
IngestDate | Tue Sep 17 21:17:43 EDT 2024 Sat Aug 17 02:27:58 EDT 2024 Thu Oct 10 22:08:12 EDT 2024 Fri Feb 23 00:20:00 EST 2024 Fri Feb 02 04:41:14 EST 2024 Thu Aug 22 11:31:31 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 16 |
Language | English |
License | Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c465t-15465248c9da550ddf7335255e3ea5bb77b65d8dbb4a35898e9af952e86dd0873 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
ORCID | 0000-0002-5429-7888 0000-0003-3454-0630 0000-0001-8795-9131 0000-0002-0199-1366 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405974/ |
PMID | 36010869 |
PQID | 2706125788 |
PQPubID | 2032421 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_9405974 proquest_miscellaneous_2707610805 proquest_journals_2706125788 gale_infotracmisc_A724393211 gale_infotracacademiconefile_A724393211 crossref_primary_10_3390_cancers14163876 |
PublicationCentury | 2000 |
PublicationDate | 2022-08-01 |
PublicationDateYYYYMMDD | 2022-08-01 |
PublicationDate_xml | – month: 08 year: 2022 text: 2022-08-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Basel |
PublicationPlace_xml | – name: Basel |
PublicationTitle | Cancers |
PublicationYear | 2022 |
Publisher | MDPI AG MDPI |
Publisher_xml | – name: MDPI AG – name: MDPI |
References | Untch (ref_62) 2011; 125 Charfare (ref_6) 2005; 92 Guillen (ref_193) 2022; 3 Narasimhan (ref_199) 2020; 26 Soran (ref_171) 2016; 36 ref_135 Kantor (ref_173) 2019; 26 Bertucci (ref_160) 2014; 355 Cardoso (ref_3) 2019; 30 Untch (ref_7) 2012; 30 Ma (ref_48) 2014; 353 Krol (ref_150) 2021; 125 Asaoka (ref_8) 2020; 14 ref_125 Rodriguez (ref_179) 2015; 33 Cain (ref_106) 2019; 173 Dieci (ref_183) 2022; 28 Rahman (ref_32) 2021; 14 Novellasdemunt (ref_185) 2020; 319 Hendry (ref_65) 2017; 24 Schelling (ref_119) 2000; 18 Lee (ref_46) 2011; 104 Spillane (ref_152) 2020; 181 Sannachi (ref_112) 2019; 12 Sachs (ref_189) 2018; 172 Osapoetra (ref_116) 2021; 12 Ueno (ref_169) 2014; 19 Park (ref_47) 2010; 16 Kwa (ref_155) 2017; 14 ref_78 Cubukcu (ref_136) 2021; 11 Zhou (ref_148) 2022; 28 Peeters (ref_176) 2013; 139 Marsh (ref_44) 2007; 7 Prat (ref_24) 2011; 5 AlSaleh (ref_170) 2021; 7 Gambardella (ref_39) 2022; 13 Bidard (ref_151) 2018; 110 Houssami (ref_11) 2012; 48 Taleghamar (ref_115) 2021; 11 Zhang (ref_79) 2019; 40 ref_149 Sung (ref_1) 2021; 71 Altinay (ref_72) 2021; 34 Cullinane (ref_130) 2020; 20 Untch (ref_93) 2016; 17 ref_140 Marczyk (ref_16) 2022; 33 ref_142 Bounova (ref_198) 2015; 161 ref_141 Mauri (ref_5) 2005; 97 Sparano (ref_163) 2018; 379 Krawczyk (ref_153) 2020; 80 Tuasha (ref_30) 2020; 2020 Sestak (ref_157) 2019; 176 Straver (ref_175) 2010; 119 Ignatiadis (ref_70) 2019; 111 Maldonado (ref_35) 2020; 10 Hussain (ref_97) 2021; 20 Focke (ref_59) 2017; 84 Zong (ref_50) 2021; 46 Schmid (ref_202) 2022; 386 Campbell (ref_54) 2018; 9 Corti (ref_134) 2021; 150 Wang (ref_52) 2012; 24 Golden (ref_103) 2013; 20 Granat (ref_188) 2019; 2 Loibl (ref_74) 2019; 30 Magbanua (ref_137) 2021; 32 Cardoso (ref_4) 2020; 31 Tadayyon (ref_114) 2016; 7 Bianchini (ref_69) 2015; 26 Soliman (ref_159) 2020; 27 Hugh (ref_20) 2009; 27 Li (ref_126) 2018; 9 Ueno (ref_107) 2018; 286 Rouzier (ref_22) 2005; 11 Lee (ref_120) 2016; 57 Nemeth (ref_99) 2021; 34 Tadayyon (ref_111) 2017; 7 Li (ref_98) 2021; 13 Guarini (ref_132) 2020; 123 Lee (ref_34) 2020; 52 Thekkekara (ref_166) 2019; 37 Parker (ref_18) 2009; 27 Karaayvaz (ref_37) 2018; 9 Wu (ref_105) 2016; 44 Li (ref_55) 2017; 13 McDonald (ref_147) 2019; 11 Riva (ref_144) 2017; 63 Lehmann (ref_26) 2011; 121 Salgado (ref_91) 2015; 1 ref_109 Shen (ref_61) 2021; 11 Wensink (ref_194) 2021; 5 Yoon (ref_33) 2019; 25 Untch (ref_67) 2016; 22 Fernandes (ref_113) 2019; 12 Silva (ref_145) 2019; 25 Gnant (ref_177) 2014; 25 Tagliafico (ref_94) 2020; 49 Cortazar (ref_9) 2014; 384 Yang (ref_190) 2020; 24 Wang (ref_49) 2017; 14 Vogel (ref_87) 2008; 100 Braman (ref_108) 2019; 2 Bader (ref_121) 2005; 46 Dasgupta (ref_117) 2020; 11 Ebrahimi (ref_186) 2022; 141 Reisenbichler (ref_84) 2020; 33 Ohara (ref_181) 2019; 173 Paydary (ref_118) 2019; 21 Schiavon (ref_143) 2015; 7 ref_15 Marra (ref_23) 2020; 6 Bhatia (ref_201) 2022; 82 Solinas (ref_63) 2017; 57 Liu (ref_95) 2019; 25 Janni (ref_154) 2016; 22 Bray (ref_43) 2010; 102 Chen (ref_58) 2017; 13 ref_25 Chang (ref_165) 2008; 108 Foo (ref_200) 2022; 10 Fowler (ref_101) 2017; 285 Schmid (ref_81) 2020; 382 Untch (ref_89) 2018; 36 Huang (ref_96) 2021; 9 Denkert (ref_68) 2018; 19 Cardoso (ref_174) 2016; 375 Mittendorf (ref_82) 2020; 396 Gianni (ref_164) 2005; 23 Beaver (ref_138) 2014; 20 Kaufmann (ref_86) 2010; 28 Dubsky (ref_158) 2020; 134 Chae (ref_128) 2018; 25 Flood (ref_192) 2022; 29 Noel (ref_75) 2020; 49 Schmid (ref_80) 2020; 31 Haynes (ref_27) 2017; 36 Schneeweiss (ref_90) 2014; 15 Guo (ref_127) 2019; 8 Harbeck (ref_13) 2019; 5 Turner (ref_29) 2021; 321 Scholzen (ref_56) 2000; 182 (ref_167) 2021; 56 Ko (ref_104) 2016; 95 Pauli (ref_196) 2017; 7 Kimbung (ref_180) 2018; 142 Wang (ref_187) 2022; 12 Perou (ref_17) 2000; 406 Perou (ref_19) 2001; 98 Nielsen (ref_57) 2021; 113 Cooks (ref_85) 2021; 13 Filipits (ref_156) 2011; 17 Ozretic (ref_53) 2018; 33 Loibl (ref_71) 2017; 28 Untch (ref_88) 2010; 28 Xue (ref_129) 2019; 98 Sannachi (ref_110) 2014; 5 Schumacher (ref_60) 2019; 19 Kolios (ref_100) 2021; 12 ref_51 Haque (ref_10) 2018; 170 Luo (ref_42) 2021; 22 Zardavas (ref_28) 2015; 12 Dieci (ref_92) 2016; 27 ref_182 Luo (ref_124) 2016; 95 Cortazar (ref_12) 2015; 22 Zhou (ref_31) 2021; 23 Prat (ref_178) 2016; 22 Morice (ref_195) 2021; 125 ref_161 Nagle (ref_184) 2018; 53 Zhao (ref_36) 2021; 82 Zhu (ref_131) 2021; 11 Shimizu (ref_168) 2009; 18 Andre (ref_162) 2019; 37 Ooft (ref_197) 2021; 6 Salgado (ref_64) 2015; 26 Vishnubalaji (ref_38) 2021; 23 Denkert (ref_73) 2015; 33 Bianchini (ref_83) 2020; 31 Tahmassebi (ref_102) 2019; 54 Li (ref_122) 2020; 47 Butler (ref_146) 2019; 5 Tiede (ref_14) 2021; 125 Vranic (ref_77) 2021; 72 Denkert (ref_66) 2010; 28 Alimirzaie (ref_139) 2019; 95 Pease (ref_172) 2019; 26 Carey (ref_21) 2016; 34 ref_45 Loi (ref_2) 2019; 30 ref_41 Beninato (ref_133) 2021; 16 ref_40 (ref_123) 2018; 32 ref_191 Denkert (ref_76) 2017; 389 |
References_xml | – volume: 142 start-page: 618 year: 2018 ident: ref_180 article-title: Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial publication-title: Int. J. Cancer doi: 10.1002/ijc.31070 contributor: fullname: Kimbung – volume: 10 start-page: 12728 year: 2020 ident: ref_35 article-title: Unveiling functional heterogeneity in breast cancer multicellular tumor spheroids through single-cell RNA-seq publication-title: Sci. Rep. doi: 10.1038/s41598-020-69026-7 contributor: fullname: Maldonado – volume: 28 start-page: 105 year: 2010 ident: ref_66 article-title: Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2009.23.7370 contributor: fullname: Denkert – volume: 26 start-page: 259 year: 2015 ident: ref_64 article-title: The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILs Working Group 2014 publication-title: Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. doi: 10.1093/annonc/mdu450 contributor: fullname: Salgado – volume: 14 start-page: 595 year: 2017 ident: ref_155 article-title: Clinical utility of gene-expression signatures in early stage breast cancer publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/nrclinonc.2017.74 contributor: fullname: Kwa – volume: 95 start-page: 643 year: 2019 ident: ref_139 article-title: Liquid biopsy in breast cancer: A comprehensive review publication-title: Clin. Genet. doi: 10.1111/cge.13514 contributor: fullname: Alimirzaie – volume: 9 start-page: 861 year: 2018 ident: ref_126 article-title: The value of neutrophil-to-lymphocyte ratio for response and prognostic effect of neoadjuvant chemotherapy in solid tumors: A systematic review and meta-analysis publication-title: J. Cancer doi: 10.7150/jca.23367 contributor: fullname: Li – volume: 23 start-page: 151 year: 2021 ident: ref_38 article-title: Transcriptional landscape associated with TNBC resistance to neoadjuvant chemotherapy revealed by single-cell RNA-seq publication-title: Mol. Ther.-Oncolytics doi: 10.1016/j.omto.2021.09.002 contributor: fullname: Vishnubalaji – volume: 37 start-page: 1956 year: 2019 ident: ref_162 article-title: Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women with Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update—Integration of Results From TAILORx publication-title: J. Clin. Oncol. doi: 10.1200/JCO.19.00945 contributor: fullname: Andre – volume: 14 start-page: 5890 year: 2017 ident: ref_49 article-title: CD44(+)/CD24(-) phenotype predicts a poor prognosis in triple-negative breast cancer publication-title: Oncol. Lett. contributor: fullname: Wang – volume: 173 start-page: 533 year: 2019 ident: ref_181 article-title: PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer publication-title: Breast Cancer Res. Treat. doi: 10.1007/s10549-018-5020-7 contributor: fullname: Ohara – volume: 141 start-page: 193 year: 2022 ident: ref_186 article-title: The potential application of organoids in breast cancer research and treatment publication-title: Hum. Genet. doi: 10.1007/s00439-021-02390-0 contributor: fullname: Ebrahimi – volume: 71 start-page: 209 year: 2021 ident: ref_1 article-title: Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries publication-title: CA Cancer J. Clin. doi: 10.3322/caac.21660 contributor: fullname: Sung – ident: ref_40 doi: 10.3390/ijms22179644 – volume: 11 start-page: 14662 year: 2021 ident: ref_136 article-title: Low pan-immune-inflammation-value predicts better chemotherapy response and survival in breast cancer patients treated with neoadjuvant chemotherapy publication-title: Sci. Rep. doi: 10.1038/s41598-021-94184-7 contributor: fullname: Cubukcu – ident: ref_45 doi: 10.1186/1471-2350-13-45 – volume: 46 start-page: 138 year: 2021 ident: ref_50 article-title: HORMAD1 promotes docetaxel resistance in triple negative breast cancer by enhancing DNA damage tolerance Corrigendum in /10.3892/or.2021.8146 publication-title: Oncol. Rep. doi: 10.3892/or.2021.8089 contributor: fullname: Zong – volume: 10 start-page: 10 year: 2022 ident: ref_200 article-title: Clinical translation of patient-derived tumour organoids- bottlenecks and strategies publication-title: Biomark. Res. doi: 10.1186/s40364-022-00356-6 contributor: fullname: Foo – ident: ref_109 doi: 10.1371/journal.pone.0236182 – volume: 386 start-page: 556 year: 2022 ident: ref_202 article-title: Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2112651 contributor: fullname: Schmid – volume: 14 start-page: 101183 year: 2021 ident: ref_32 article-title: Prediction of chemotherapy response in breast cancer patients at pre-treatment using second derivative texture of CT images and machine learning publication-title: Transl. Oncol. doi: 10.1016/j.tranon.2021.101183 contributor: fullname: Rahman – volume: 102 start-page: 1003 year: 2010 ident: ref_43 article-title: Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide publication-title: Br. J. Cancer doi: 10.1038/sj.bjc.6605587 contributor: fullname: Bray – volume: 7 start-page: 811 year: 2021 ident: ref_170 article-title: Response to Induction Neoadjuvant Hormonal Therapy Using Upfront 21-Gene Breast Recurrence Score Assay-Results From the SAFIA Phase III Trial publication-title: JCO Glob. Oncol. doi: 10.1200/GO.20.00575 contributor: fullname: AlSaleh – volume: 13 start-page: 4910 year: 2021 ident: ref_85 article-title: Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group publication-title: Cancers doi: 10.3390/cancers13194910 contributor: fullname: Cooks – volume: 27 start-page: 765 year: 2020 ident: ref_159 article-title: Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer publication-title: Ann. Surg. Oncol. doi: 10.1245/s10434-019-08039-7 contributor: fullname: Soliman – ident: ref_15 doi: 10.3390/cancers12082012 – volume: 7 start-page: 302ra133 year: 2015 ident: ref_143 article-title: Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer publication-title: Sci. Transl. Med. contributor: fullname: Schiavon – volume: 19 start-page: 607 year: 2014 ident: ref_169 article-title: Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer publication-title: Int. J. Clin. Oncol. doi: 10.1007/s10147-013-0614-x contributor: fullname: Ueno – volume: 84 start-page: 219 year: 2017 ident: ref_59 article-title: Interlaboratory variability of Ki67 staining in breast cancer publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2017.07.041 contributor: fullname: Focke – volume: 6 start-page: 54 year: 2020 ident: ref_23 article-title: Practical classification of triple-negative breast cancer: Intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies publication-title: NPJ Breast Cancer doi: 10.1038/s41523-020-00197-2 contributor: fullname: Marra – volume: 7 start-page: 45094 year: 2016 ident: ref_114 article-title: Quantitative ultrasound assessment of breast tumor response to chemotherapy using a multi-parameter approach publication-title: Oncotarget doi: 10.18632/oncotarget.8862 contributor: fullname: Tadayyon – volume: 26 start-page: 3662 year: 2020 ident: ref_199 article-title: Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy publication-title: Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. doi: 10.1158/1078-0432.CCR-20-0073 contributor: fullname: Narasimhan – volume: 25 start-page: 3538 year: 2019 ident: ref_95 article-title: Radiomics of Multiparametric MRI for Pretreatment Prediction of Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer: A Multicenter Study publication-title: Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. doi: 10.1158/1078-0432.CCR-18-3190 contributor: fullname: Liu – volume: 57 start-page: 1183 year: 2016 ident: ref_120 article-title: The Prognostic Impact of Early Change in 18F-FDG PET SUV After Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer publication-title: J. Nucl. Med. Off. Publ. Soc. Nucl. Med. contributor: fullname: Lee – volume: 134 start-page: 99 year: 2020 ident: ref_158 article-title: The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2020.04.020 contributor: fullname: Dubsky – volume: 40 start-page: 143 year: 2019 ident: ref_79 article-title: The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer publication-title: Ann. Diagn. Pathol. doi: 10.1016/j.anndiagpath.2019.04.004 contributor: fullname: Zhang – volume: 16 start-page: 529 year: 2021 ident: ref_133 article-title: The Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line Therapy publication-title: Target. Oncol. doi: 10.1007/s11523-021-00819-0 contributor: fullname: Beninato – ident: ref_161 doi: 10.3390/cancers12051133 – volume: 28 start-page: 2024 year: 2010 ident: ref_88 article-title: Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: Results from the GeparQuattro study publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2009.23.8451 contributor: fullname: Untch – volume: 12 start-page: 1382 year: 2022 ident: ref_187 article-title: Patient-Derived Tumor Organoids: New Progress and Opportunities to Facilitate Precision Cancer Immunotherapy publication-title: Front. Oncol. contributor: fullname: Wang – volume: 20 start-page: 1059 year: 2013 ident: ref_103 article-title: Dynamic contrast-enhanced MRI-based biomarkers of therapeutic response in triple-negative breast cancer publication-title: J. Am. Med. Inform. Assoc. doi: 10.1136/amiajnl-2012-001460 contributor: fullname: Golden – volume: 2020 start-page: 4736091 year: 2020 ident: ref_30 article-title: Heterogeneity of Tumors in Breast Cancer: Implications and Prospects for Prognosis and Therapeutics publication-title: Scientifica doi: 10.1155/2020/4736091 contributor: fullname: Tuasha – volume: 13 start-page: 1021 year: 2017 ident: ref_55 article-title: Prognostic values of Ki-67 in neoadjuvant setting for breast cancer: A systematic review and meta-analysis publication-title: Future Oncol. doi: 10.2217/fon-2016-0428 contributor: fullname: Li – volume: 52 start-page: 1428 year: 2020 ident: ref_34 article-title: Single-cell multiomics: Technologies and data analysis methods publication-title: Exp. Mol. Med. doi: 10.1038/s12276-020-0420-2 contributor: fullname: Lee – volume: 24 start-page: 235 year: 2017 ident: ref_65 article-title: Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research publication-title: Adv. Anat. Pathol. doi: 10.1097/PAP.0000000000000162 contributor: fullname: Hendry – volume: 5 start-page: 30 year: 2021 ident: ref_194 article-title: Patient-derived organoids as a predictive biomarker for treatment response in cancer patients publication-title: NPJ Precis. Oncol. doi: 10.1038/s41698-021-00168-1 contributor: fullname: Wensink – volume: 28 start-page: 697 year: 2022 ident: ref_148 article-title: Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response publication-title: Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. doi: 10.1158/1078-0432.CCR-21-3231 contributor: fullname: Zhou – volume: 11 start-page: 504 year: 2019 ident: ref_147 article-title: Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.aax7392 contributor: fullname: McDonald – volume: 33 start-page: 1746 year: 2020 ident: ref_84 article-title: Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer publication-title: Mod. Pathol. doi: 10.1038/s41379-020-0544-x contributor: fullname: Reisenbichler – volume: 161 start-page: 933 year: 2015 ident: ref_198 article-title: Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients publication-title: Cell doi: 10.1016/j.cell.2015.03.053 contributor: fullname: Bounova – volume: 11 start-page: 632357 year: 2021 ident: ref_61 article-title: Meta-Analysis of HER2-Enriched Subtype Predicting the Pathological Complete Response within HER2-Positive Breast Cancer in Patients Who Received Neoadjuvant Treatment publication-title: Front. Oncol. doi: 10.3389/fonc.2021.632357 contributor: fullname: Shen – volume: 54 start-page: 110 year: 2019 ident: ref_102 article-title: Impact of Machine Learning with Multiparametric Magnetic Resonance Imaging of the Breast for Early Prediction of Response to Neoadjuvant Chemotherapy and Survival Outcomes in Breast Cancer Patients publication-title: Investig. Radiol. doi: 10.1097/RLI.0000000000000518 contributor: fullname: Tahmassebi – volume: 7 start-page: 45733 year: 2017 ident: ref_111 article-title: A priori Prediction of Neoadjuvant Chemotherapy Response and Survival in Breast Cancer Patients using Quantitative Ultrasound publication-title: Sci. Rep. doi: 10.1038/srep45733 contributor: fullname: Tadayyon – volume: 7 start-page: 362 year: 2007 ident: ref_44 article-title: Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer publication-title: Pharm. J. contributor: fullname: Marsh – volume: 44 start-page: 1107 year: 2016 ident: ref_105 article-title: Intratumor partitioning and texture analysis of dynamic contrast-enhanced (DCE)-MRI identifies relevant tumor subregions to predict pathological response of breast cancer to neoadjuvant chemotherapy publication-title: J. Magn. Reson. Imaging doi: 10.1002/jmri.25279 contributor: fullname: Wu – volume: 2 start-page: e192561 year: 2019 ident: ref_108 article-title: Association of Peritumoral Radiomics with Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 (ERBB2)-Positive Breast Cancer publication-title: JAMA Netw. Open doi: 10.1001/jamanetworkopen.2019.2561 contributor: fullname: Braman – volume: 33 start-page: 983 year: 2015 ident: ref_73 article-title: Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2014.58.1967 contributor: fullname: Denkert – volume: 37 start-page: e12093 year: 2019 ident: ref_166 article-title: Predicting response to neoadjuvant chemotherapy in nonmetastatic hormone receptor-positive breast cancer using 21-gene Breast Recurrence Score test publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2019.37.15_suppl.e12093 contributor: fullname: Thekkekara – volume: 95 start-page: e2453 year: 2016 ident: ref_104 article-title: Assessment of Invasive Breast Cancer Heterogeneity Using Whole-Tumor Magnetic Resonance Imaging Texture Analysis: Correlations With Detailed Pathological Findings publication-title: Medicine doi: 10.1097/MD.0000000000002453 contributor: fullname: Ko – volume: 28 start-page: 497 year: 2017 ident: ref_71 article-title: Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: A subanalysis of data from the randomized phase III GeparSepto trial publication-title: Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. doi: 10.1093/annonc/mdw610 contributor: fullname: Loibl – volume: 28 start-page: 537 year: 2010 ident: ref_86 article-title: Long-term results from the neoadjuvant GeparDuo trial: A randomized, multicenter, open phase III study comparing a dose-intensified 8-week schedule of doxorubicin hydrochloride and docetaxel (ADoc) with a sequential 24-week schedule of doxorubicin hydrochloride/cyclophosphamide followed by docetaxel (AC-Doc) regimen as preoperative therapy (NACT) in patients (pts) with operable breast cancer (BC) publication-title: J. Clin. Oncol. doi: 10.1200/jco.2010.28.15_suppl.537 contributor: fullname: Kaufmann – volume: 95 start-page: e2914 year: 2016 ident: ref_124 article-title: The Value of 18F-FDG PET/CT Imaging Combined with Pretherapeutic Ki67 for Early Prediction of Pathologic Response after Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer publication-title: Medicine doi: 10.1097/MD.0000000000002914 contributor: fullname: Luo – volume: 15 start-page: 747 year: 2014 ident: ref_90 article-title: Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): A randomised phase 2 trial publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(14)70160-3 contributor: fullname: Schneeweiss – ident: ref_41 doi: 10.3390/ijms23031665 – volume: 33 start-page: 814 year: 2022 ident: ref_16 article-title: Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials publication-title: Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. doi: 10.1016/j.annonc.2022.04.072 contributor: fullname: Marczyk – volume: 20 start-page: 2643 year: 2014 ident: ref_138 article-title: Detection of cancer DNA in plasma of patients with early-stage breast cancer publication-title: Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. doi: 10.1158/1078-0432.CCR-13-2933 contributor: fullname: Beaver – volume: 170 start-page: 559 year: 2018 ident: ref_10 article-title: Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy publication-title: Breast Cancer Res. Treat. doi: 10.1007/s10549-018-4801-3 contributor: fullname: Haque – volume: 5 start-page: 5 year: 2011 ident: ref_24 article-title: Deconstructing the molecular portraits of breast cancer publication-title: Mol. Oncol. doi: 10.1016/j.molonc.2010.11.003 contributor: fullname: Prat – volume: 379 start-page: 111 year: 2018 ident: ref_163 article-title: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1804710 contributor: fullname: Sparano – volume: 19 start-page: e741 year: 2019 ident: ref_60 article-title: Does Tumor Size Predict Response to Neoadjuvant Chemotherapy in the Modern Era of Biologically Driven Treatment? A Nationwide Study of US Breast Cancer Patients publication-title: Clin. Breast Cancer doi: 10.1016/j.clbc.2019.05.014 contributor: fullname: Schumacher – volume: 25 start-page: 373 year: 2019 ident: ref_33 article-title: Predicting neo-adjuvant chemotherapy response and progression-free survival of locally advanced breast cancer using textural features of intratumoral heterogeneity on F-18 FDG PET/CT and diffusion-weighted MR imaging publication-title: Breast J. doi: 10.1111/tbj.13032 contributor: fullname: Yoon – volume: 24 start-page: 348 year: 2012 ident: ref_52 article-title: Clusterin confers resistance to TNF-alpha-induced apoptosis in breast cancer cells through NF-kappaB activation and Bcl-2 overexpression publication-title: J. Chemother. doi: 10.1179/1973947812Y.0000000049 contributor: fullname: Wang – volume: 34 start-page: 2130 year: 2021 ident: ref_72 article-title: Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: The IVITA study publication-title: Mod. Pathol. doi: 10.1038/s41379-021-00865-z contributor: fullname: Altinay – volume: 119 start-page: 551 year: 2010 ident: ref_175 article-title: The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer publication-title: Breast Cancer Res. Treat. doi: 10.1007/s10549-009-0333-1 contributor: fullname: Straver – volume: 12 start-page: 1177 year: 2019 ident: ref_113 article-title: Monitoring Breast Cancer Response to Neoadjuvant Chemotherapy Using Ultrasound Strain Elastography publication-title: Transl. Oncol. doi: 10.1016/j.tranon.2019.05.004 contributor: fullname: Fernandes – volume: 9 start-page: 19 year: 2018 ident: ref_54 article-title: MCL-1 is a prognostic indicator and drug target in breast cancer publication-title: Cell Death Dis. doi: 10.1038/s41419-017-0035-2 contributor: fullname: Campbell – volume: 57 start-page: 8 year: 2017 ident: ref_63 article-title: Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials publication-title: Cancer Treat. Rev. doi: 10.1016/j.ctrv.2017.04.005 contributor: fullname: Solinas – volume: 108 start-page: 233 year: 2008 ident: ref_165 article-title: Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients publication-title: Breast Cancer Res. Treat. doi: 10.1007/s10549-007-9590-z contributor: fullname: Chang – volume: 14 start-page: 1178223420980377 year: 2020 ident: ref_8 article-title: Neoadjuvant Chemotherapy for Breast Cancer: Past, Present, and Future publication-title: Breast Cancer Basic Clin. Res. doi: 10.1177/1178223420980377 contributor: fullname: Asaoka – volume: 5 start-page: a003772 year: 2019 ident: ref_146 article-title: Circulating tumor DNA dynamics using patient-customized assays are associated with outcome in neoadjuvantly treated breast cancer publication-title: Cold Spring Harb. Mol. Case Stud. doi: 10.1101/mcs.a003772 contributor: fullname: Butler – volume: 3 start-page: 232 year: 2022 ident: ref_193 article-title: A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology publication-title: Nat. Cancer doi: 10.1038/s43018-022-00337-6 contributor: fullname: Guillen – volume: 11 start-page: 5678 year: 2005 ident: ref_22 article-title: Breast cancer molecular subtypes respond differently to preoperative chemotherapy publication-title: Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. doi: 10.1158/1078-0432.CCR-04-2421 contributor: fullname: Rouzier – volume: 384 start-page: 164 year: 2014 ident: ref_9 article-title: Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis publication-title: Lancet doi: 10.1016/S0140-6736(13)62422-8 contributor: fullname: Cortazar – volume: 12 start-page: 381 year: 2015 ident: ref_28 article-title: Clinical management of breast cancer heterogeneity publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/nrclinonc.2015.73 contributor: fullname: Zardavas – volume: 5 start-page: 3497 year: 2014 ident: ref_110 article-title: Early prediction of therapy responses and outcomes in breast cancer patients using quantitative ultrasound spectral texture publication-title: Oncotarget doi: 10.18632/oncotarget.1950 contributor: fullname: Sannachi – volume: 30 start-page: 1183 year: 2019 ident: ref_2 article-title: The ESMO clinical practise guidelines for early breast cancer: Diagnosis, treatment and follow-up: On the winding road to personalized medicine publication-title: Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. doi: 10.1093/annonc/mdz201 contributor: fullname: Loi – volume: 9 start-page: 662749 year: 2021 ident: ref_96 article-title: Prediction of Tumor Shrinkage Pattern to Neoadjuvant Chemotherapy Using a Multiparametric MRI-Based Machine Learning Model in Patients With Breast Cancer publication-title: Front. Bioeng. Biotechnol. doi: 10.3389/fbioe.2021.662749 contributor: fullname: Huang – volume: 31 start-page: 1623 year: 2020 ident: ref_4 article-title: 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) publication-title: Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. doi: 10.1016/j.annonc.2020.09.010 contributor: fullname: Cardoso – volume: 12 start-page: 1271 year: 2019 ident: ref_112 article-title: Breast Cancer Treatment Response Monitoring Using Quantitative Ultrasound and Texture Analysis: Comparative Analysis of Analytical Models publication-title: Transl. Oncol. doi: 10.1016/j.tranon.2019.06.004 contributor: fullname: Sannachi – volume: 125 start-page: 23 year: 2021 ident: ref_150 article-title: Detection of clustered circulating tumour cells in early breast cancer publication-title: Br. J. Cancer doi: 10.1038/s41416-021-01327-8 contributor: fullname: Krol – volume: 139 start-page: 759 year: 2013 ident: ref_176 article-title: Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy publication-title: Breast Cancer Res. Treat. doi: 10.1007/s10549-013-2572-4 contributor: fullname: Peeters – volume: 98 start-page: 10869 year: 2001 ident: ref_19 article-title: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.191367098 contributor: fullname: Perou – volume: 25 start-page: 3581 year: 2019 ident: ref_145 article-title: Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial publication-title: Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. doi: 10.1158/1078-0432.CCR-18-2521 contributor: fullname: Silva – volume: 16 start-page: 876 year: 2010 ident: ref_47 article-title: Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer publication-title: Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. doi: 10.1158/1078-0432.CCR-09-1532 contributor: fullname: Park – volume: 48 start-page: 3342 year: 2012 ident: ref_11 article-title: Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2012.05.023 contributor: fullname: Houssami – volume: 80 start-page: 1093 year: 2020 ident: ref_153 article-title: Liquid Biopsy in Breast Cancer publication-title: Geburtshilfe Und Frauenheilkd. doi: 10.1055/a-1124-7225 contributor: fullname: Krawczyk – volume: 125 start-page: 164 year: 2021 ident: ref_14 article-title: Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression publication-title: Br. J. Cancer doi: 10.1038/s41416-021-01328-7 contributor: fullname: Tiede – volume: 26 start-page: 366 year: 2019 ident: ref_172 article-title: Oncotype DX(®) Recurrence Score as a Predictor of Response to Neoadjuvant Chemotherapy publication-title: Ann. Surg. Oncol. doi: 10.1245/s10434-018-07107-8 contributor: fullname: Pease – volume: 23 start-page: 7265 year: 2005 ident: ref_164 article-title: Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2005.02.0818 contributor: fullname: Gianni – volume: 319 start-page: C151 year: 2020 ident: ref_185 article-title: A brief history of organoids publication-title: Am. J. Physiol. Cell Physiol. doi: 10.1152/ajpcell.00120.2020 contributor: fullname: Novellasdemunt – volume: 18 start-page: 171 year: 2009 ident: ref_168 article-title: 21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients publication-title: Breast doi: 10.1016/j.breast.2009.03.005 contributor: fullname: Shimizu – volume: 5 start-page: 66 year: 2019 ident: ref_13 article-title: Breast cancer publication-title: Nat. Rev. Dis. Primers doi: 10.1038/s41572-019-0111-2 contributor: fullname: Harbeck – volume: 285 start-page: 358 year: 2017 ident: ref_101 article-title: Imaging Neoadjuvant Therapy Response in Breast Cancer publication-title: Radiology doi: 10.1148/radiol.2017170180 contributor: fullname: Fowler – volume: 173 start-page: 455 year: 2019 ident: ref_106 article-title: Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: A study using an independent validation set publication-title: Breast Cancer Res. Treat. doi: 10.1007/s10549-018-4990-9 contributor: fullname: Cain – volume: 82 start-page: 1174 year: 2022 ident: ref_201 article-title: Patient-Derived Triple-Negative Breast Cancer Organoids Provide Robust Model Systems That Recapitulate Tumor Intrinsic Characteristics publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-21-2807 contributor: fullname: Bhatia – volume: 34 start-page: 542 year: 2016 ident: ref_21 article-title: Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2015.62.1268 contributor: fullname: Carey – volume: 32 start-page: 229 year: 2021 ident: ref_137 article-title: Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival publication-title: Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. doi: 10.1016/j.annonc.2020.11.007 contributor: fullname: Magbanua – volume: 181 start-page: 571 year: 2020 ident: ref_152 article-title: Circulating tumour cell enumeration does not correlate with Miller-Payne grade in a cohort of breast cancer patients undergoing neoadjuvant chemotherapy publication-title: Breast Cancer Res. Treat. doi: 10.1007/s10549-020-05658-7 contributor: fullname: Spillane – volume: 27 start-page: 1160 year: 2009 ident: ref_18 article-title: Supervised risk predictor of breast cancer based on intrinsic subtypes publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2008.18.1370 contributor: fullname: Parker – volume: 24 start-page: 5420 year: 2020 ident: ref_190 article-title: Progress in the application of organoids to breast cancer research publication-title: J. Cell. Mol. Med. doi: 10.1111/jcmm.15216 contributor: fullname: Yang – volume: 321 start-page: C343 year: 2021 ident: ref_29 article-title: Heterogeneity within molecular subtypes of breast cancer publication-title: Am. J. Physiol. Cell Physiol. doi: 10.1152/ajpcell.00109.2021 contributor: fullname: Turner – volume: 104 start-page: 1730 year: 2011 ident: ref_46 article-title: An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer publication-title: Br. J. Cancer doi: 10.1038/bjc.2011.159 contributor: fullname: Lee – volume: 17 start-page: 6012 year: 2011 ident: ref_156 article-title: A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors publication-title: Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. doi: 10.1158/1078-0432.CCR-11-0926 contributor: fullname: Filipits – volume: 286 start-page: 412 year: 2018 ident: ref_107 article-title: Features from Computerized Texture Analysis of Breast Cancers at Pretreatment MR Imaging Are Associated with Response to Neoadjuvant Chemotherapy publication-title: Radiology doi: 10.1148/radiol.2017170143 contributor: fullname: Ueno – volume: 27 start-page: 1867 year: 2016 ident: ref_92 article-title: Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial publication-title: Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. doi: 10.1093/annonc/mdw262 contributor: fullname: Dieci – ident: ref_140 doi: 10.3390/cancers13153813 – ident: ref_149 doi: 10.3390/cancers13102356 – volume: 11 start-page: 1350 year: 2021 ident: ref_131 article-title: Development of a predictive model utilizing the neutrophil to lymphocyte ratio to predict neoadjuvant chemotherapy efficacy in early breast cancer patients publication-title: Sci. Rep. doi: 10.1038/s41598-020-80037-2 contributor: fullname: Zhu – volume: 8 start-page: 4135 year: 2019 ident: ref_127 article-title: Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: An updated meta-analysis of 17079 individuals publication-title: Cancer Med. doi: 10.1002/cam4.2281 contributor: fullname: Guo – volume: 1 start-page: 448 year: 2015 ident: ref_91 article-title: Tumor-Infiltrating Lymphocytes and Associations with Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated with Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2015.0830 contributor: fullname: Salgado – ident: ref_125 doi: 10.3390/cancers12040958 – volume: 31 start-page: S1145 year: 2020 ident: ref_83 article-title: LBA13 Tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trial publication-title: Ann. Oncol. doi: 10.1016/j.annonc.2020.08.2241 contributor: fullname: Bianchini – volume: 20 start-page: e675 year: 2020 ident: ref_130 article-title: Can the Neutrophil to Lymphocyte Ratio Predict Complete Pathologic Response to Neoadjuvant Breast Cancer Treatment? A Systematic Review and Meta-analysis publication-title: Clin. Breast Cancer doi: 10.1016/j.clbc.2020.05.008 contributor: fullname: Cullinane – volume: 36 start-page: 65 year: 2016 ident: ref_171 article-title: The impact of Oncotype DX® recurrence score of paraffin-embedded core biopsy tissues in predicting response to neoadjuvant chemotherapy in women with breast cancer publication-title: Breast Dis. doi: 10.3233/BD-150199 contributor: fullname: Soran – volume: 97 start-page: 188 year: 2005 ident: ref_5 article-title: Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis publication-title: J. Natl. Cancer Inst. doi: 10.1093/jnci/dji021 contributor: fullname: Mauri – ident: ref_25 doi: 10.1371/journal.pone.0157368 – volume: 17 start-page: 345 year: 2016 ident: ref_93 article-title: Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): A randomised, phase 3 trial publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(15)00542-2 contributor: fullname: Untch – volume: 353 start-page: 153 year: 2014 ident: ref_48 article-title: Enriched CD44+/CD24− population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC) publication-title: Cancer Lett. doi: 10.1016/j.canlet.2014.06.022 contributor: fullname: Ma – volume: 355 start-page: 70 year: 2014 ident: ref_160 article-title: EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer publication-title: Cancer Lett. doi: 10.1016/j.canlet.2014.09.014 contributor: fullname: Bertucci – volume: 29 start-page: 47 year: 2022 ident: ref_192 article-title: Organoids as a Robust Preclinical Model for Precision Medicine in Colorectal Cancer: A Systematic Review publication-title: Ann. Surg. Oncol. doi: 10.1245/s10434-021-10829-x contributor: fullname: Flood – volume: 172 start-page: 373 year: 2018 ident: ref_189 article-title: A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity publication-title: Cell doi: 10.1016/j.cell.2017.11.010 contributor: fullname: Sachs – volume: 56 start-page: 35 year: 2021 ident: ref_167 article-title: Selection of neoadjuvant treatment based on the 21-GENE test results in luminal breast cancer publication-title: Breast doi: 10.1016/j.breast.2021.01.001 – ident: ref_141 doi: 10.3390/cancers13215364 – ident: ref_51 doi: 10.3390/jcm5020017 – volume: 12 start-page: 81 year: 2021 ident: ref_116 article-title: A priori prediction of response in multicentre locally advanced breast cancer (LABC) patients using quantitative ultrasound and derivative texture methods publication-title: Oncotarget doi: 10.18632/oncotarget.27867 contributor: fullname: Osapoetra – volume: 92 start-page: 14 year: 2005 ident: ref_6 article-title: Neoadjuvant chemotherapy in breast cancer publication-title: Br. J. Surg. doi: 10.1002/bjs.4840 contributor: fullname: Charfare – volume: 20 start-page: 63 year: 2021 ident: ref_97 article-title: Machine learning classification of texture features of MRI breast tumor and peri-tumor of combined pre- and early treatment predicts pathologic complete response publication-title: Biomed. Eng. Online doi: 10.1186/s12938-021-00899-z contributor: fullname: Hussain – volume: 49 start-page: 151634 year: 2020 ident: ref_75 article-title: Predictive markers for pathological complete response after neo-adjuvant chemotherapy in triple-negative breast cancer publication-title: Ann. Diagn. Pathol. doi: 10.1016/j.anndiagpath.2020.151634 contributor: fullname: Noel – volume: 25 start-page: e113 year: 2018 ident: ref_128 article-title: Neutrophil-lymphocyte ratio predicts response to chemotherapy in triple-negative breast cancer publication-title: Curr. Oncol. doi: 10.3747/co.25.3888 contributor: fullname: Chae – volume: 406 start-page: 747 year: 2000 ident: ref_17 article-title: Molecular portraits of human breast tumours publication-title: Nature doi: 10.1038/35021093 contributor: fullname: Perou – volume: 382 start-page: 810 year: 2020 ident: ref_81 article-title: Pembrolizumab for Early Triple-Negative Breast Cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1910549 contributor: fullname: Schmid – volume: 27 start-page: 1168 year: 2009 ident: ref_20 article-title: Breast cancer subtypes and response to docetaxel in node-positive breast cancer: Use of an immunohistochemical definition in the BCIRG 001 trial publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2008.18.1024 contributor: fullname: Hugh – volume: 111 start-page: 69 year: 2019 ident: ref_70 article-title: Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy publication-title: J. Natl. Cancer Inst. doi: 10.1093/jnci/djy076 contributor: fullname: Ignatiadis – volume: 182 start-page: 311 year: 2000 ident: ref_56 article-title: The Ki-67 protein: From the known and the unknown publication-title: J. Cell. Physiol. doi: 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9 contributor: fullname: Scholzen – volume: 98 start-page: e13842 year: 2019 ident: ref_129 article-title: Prognostic role of high neutrophil-to-lymphocyte ratio in breast cancer patients receiving neoadjuvant chemotherapy: Meta-analysis publication-title: Medicine doi: 10.1097/MD.0000000000013842 contributor: fullname: Xue – volume: 121 start-page: 2750 year: 2011 ident: ref_26 article-title: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies publication-title: J. Clin. Investig. doi: 10.1172/JCI45014 contributor: fullname: Lehmann – volume: 33 start-page: 11049 year: 2015 ident: ref_179 article-title: Prosigna (PAM50) to predict response to neoadjuvant chemotherapy (NAC) in HR+/HER2- early breast cancer (EBC) patients publication-title: J. Clin. Oncol. doi: 10.1200/jco.2015.33.15_suppl.11049 contributor: fullname: Rodriguez – volume: 375 start-page: 717 year: 2016 ident: ref_174 article-title: 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1602253 contributor: fullname: Cardoso – volume: 113 start-page: 808 year: 2021 ident: ref_57 article-title: Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group publication-title: J. Natl. Cancer Inst. doi: 10.1093/jnci/djaa201 contributor: fullname: Nielsen – volume: 389 start-page: 2430 year: 2017 ident: ref_76 article-title: Molecular alterations in triple-negative breast cancer-the road to new treatment strategies publication-title: Lancet doi: 10.1016/S0140-6736(16)32454-0 contributor: fullname: Denkert – volume: 31 start-page: 569 year: 2020 ident: ref_80 article-title: Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: Results from the phase 1b open-label, multicohort KEYNOTE-173 study publication-title: Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. doi: 10.1016/j.annonc.2020.01.072 contributor: fullname: Schmid – volume: 53 start-page: 258 year: 2018 ident: ref_184 article-title: Patient-derived tumor organoids for prediction of cancer treatment response publication-title: Semin. Cancer Biol. doi: 10.1016/j.semcancer.2018.06.005 contributor: fullname: Nagle – volume: 6 start-page: 100103 year: 2021 ident: ref_197 article-title: Prospective experimental treatment of colorectal cancer patients based on organoid drug responses publication-title: ESMO Open doi: 10.1016/j.esmoop.2021.100103 contributor: fullname: Ooft – volume: 36 start-page: 1308 year: 2018 ident: ref_89 article-title: Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44) publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2017.75.9175 contributor: fullname: Untch – ident: ref_142 doi: 10.3390/cancers14020310 – volume: 2 start-page: 150 year: 2019 ident: ref_188 article-title: The promises and challenges of patient-derived tumor organoids in drug development and precision oncology publication-title: Anim. Models Exp. Med. doi: 10.1002/ame2.12077 contributor: fullname: Granat – volume: 100 start-page: 542 year: 2008 ident: ref_87 article-title: Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: Phase III randomized GeparTrio trial publication-title: J. Natl. Cancer Inst. doi: 10.1093/jnci/djn085 contributor: fullname: Vogel – volume: 19 start-page: 40 year: 2018 ident: ref_68 article-title: Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: A pooled analysis of 3771 patients treated with neoadjuvant therapy publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(17)30904-X contributor: fullname: Denkert – volume: 36 start-page: 547 year: 2017 ident: ref_27 article-title: Breast cancer complexity: Implications of intratumoral heterogeneity in clinical management publication-title: Cancer Metastasis Rev. doi: 10.1007/s10555-017-9684-y contributor: fullname: Haynes – volume: 22 start-page: 560 year: 2016 ident: ref_178 article-title: Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay publication-title: Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. doi: 10.1158/1078-0432.CCR-15-0630 contributor: fullname: Prat – volume: 110 start-page: 560 year: 2018 ident: ref_151 article-title: Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis publication-title: J. Natl. Cancer Inst. doi: 10.1093/jnci/djy018 contributor: fullname: Bidard – volume: 47 start-page: 1116 year: 2020 ident: ref_122 article-title: (18)F-FDG PET/CT radiomic predictors of pathologic complete response (pCR) to neoadjuvant chemotherapy in breast cancer patients publication-title: Eur. J. Nucl. Med. Mol. Imaging doi: 10.1007/s00259-020-04684-3 contributor: fullname: Li – volume: 46 start-page: 1144 year: 2005 ident: ref_121 article-title: Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET publication-title: J. Nucl. Med. Off. Publ. Soc. Nucl. Med. contributor: fullname: Bader – volume: 32 start-page: 379 year: 2018 ident: ref_123 article-title: Intratumoral heterogeneity in (18)F-FDG PET/CT by textural analysis in breast cancer as a predictive and prognostic subrogate publication-title: Ann. Nucl. Med. doi: 10.1007/s12149-018-1253-0 – volume: 11 start-page: 14865 year: 2021 ident: ref_115 article-title: Characterizing intra-tumor regions on quantitative ultrasound parametric images to predict breast cancer response to chemotherapy at pre-treatment publication-title: Sci. Rep. doi: 10.1038/s41598-021-94004-y contributor: fullname: Taleghamar – volume: 30 start-page: 1279 year: 2019 ident: ref_74 article-title: A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: Clinical results and biomarker analysis of GeparNuevo study publication-title: Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. doi: 10.1093/annonc/mdz158 contributor: fullname: Loibl – volume: 21 start-page: 1 year: 2019 ident: ref_118 article-title: The Evolving Role of FDG-PET/CT in the Diagnosis, Staging, and Treatment of Breast Cancer publication-title: Mol. Imaging Biol. doi: 10.1007/s11307-018-1181-3 contributor: fullname: Paydary – volume: 7 start-page: 462 year: 2017 ident: ref_196 article-title: Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-16-1154 contributor: fullname: Pauli – volume: 30 start-page: 1194 year: 2019 ident: ref_3 article-title: Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† publication-title: Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. doi: 10.1093/annonc/mdz173 contributor: fullname: Cardoso – volume: 49 start-page: 74 year: 2020 ident: ref_94 article-title: Overview of radiomics in breast cancer diagnosis and prognostication publication-title: Breast doi: 10.1016/j.breast.2019.10.018 contributor: fullname: Tagliafico – volume: 28 start-page: 308 year: 2022 ident: ref_183 article-title: Neoadjuvant chemotherapy and immunotherapy in Luminal B-like breast cancer: Results of the phase II GIADA trial publication-title: Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. doi: 10.1158/1078-0432.CCR-21-2260 contributor: fullname: Dieci – volume: 150 start-page: 155 year: 2021 ident: ref_134 article-title: The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2021.03.043 contributor: fullname: Corti – volume: 23 start-page: 682 year: 2021 ident: ref_31 article-title: Single-cell RNA-seq dissects the intratumoral heterogeneity of triple-negative breast cancer based on gene regulatory networks publication-title: Mol. Ther.-Nucleic Acids doi: 10.1016/j.omtn.2020.12.018 contributor: fullname: Zhou – volume: 13 start-page: 843 year: 2017 ident: ref_58 article-title: The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: A systematic review and meta-analysis publication-title: Future Oncol. doi: 10.2217/fon-2016-0420 contributor: fullname: Chen – volume: 26 start-page: 3232 year: 2019 ident: ref_173 article-title: Are we Overtreating Hormone Receptor Positive Breast Cancer with Neoadjuvant Chemotherapy? Role of OncotypeDx(®) for Hormone Receptor Positive Patients Undergoing Neoadjuvant Chemotherapy publication-title: Ann. Surg. Oncol. doi: 10.1245/s10434-019-07555-w contributor: fullname: Kantor – volume: 26 start-page: 2429 year: 2015 ident: ref_69 article-title: Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial publication-title: Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. doi: 10.1093/annonc/mdv395 contributor: fullname: Bianchini – volume: 18 start-page: 1689 year: 2000 ident: ref_119 article-title: Positron emission tomography using [(18)F] Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2000.18.8.1689 contributor: fullname: Schelling – ident: ref_191 doi: 10.3390/cancers12123869 – volume: 34 start-page: 833 year: 2021 ident: ref_99 article-title: Multicontrast MRI-based radiomics for the prediction of pathological complete response to neoadjuvant chemotherapy in patients with early triple negative breast cancer publication-title: Magma doi: 10.1007/s10334-021-00941-0 contributor: fullname: Nemeth – ident: ref_78 doi: 10.3390/cancers12092497 – volume: 396 start-page: 1090 year: 2020 ident: ref_82 article-title: Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): A randomised, double-blind, phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(20)31953-X contributor: fullname: Mittendorf – volume: 123 start-page: 403 year: 2020 ident: ref_132 article-title: The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: Results from a pooled-analysis of the Valentino and TRIBE first-line trials publication-title: Br. J. Cancer doi: 10.1038/s41416-020-0894-7 contributor: fullname: Guarini – volume: 176 start-page: 377 year: 2019 ident: ref_157 article-title: Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone publication-title: Breast Cancer Res. Treat. doi: 10.1007/s10549-019-05226-8 contributor: fullname: Sestak – volume: 9 start-page: 3588 year: 2018 ident: ref_37 article-title: Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq publication-title: Nat. Commun. doi: 10.1038/s41467-018-06052-0 contributor: fullname: Karaayvaz – volume: 125 start-page: 145 year: 2011 ident: ref_62 article-title: Impact of treatment characteristics on response of different breast cancer phenotypes: Pooled analysis of the German neo-adjuvant chemotherapy trials publication-title: Breast Cancer Res. Treat. doi: 10.1007/s10549-010-1228-x contributor: fullname: Untch – volume: 30 start-page: 1796 year: 2012 ident: ref_7 article-title: Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2011.38.8595 contributor: fullname: Untch – volume: 22 start-page: 548 year: 2021 ident: ref_42 article-title: Cytochrome P450: Implications for human breast cancer (Review) publication-title: Oncol. Lett. doi: 10.3892/ol.2021.12809 contributor: fullname: Luo – volume: 13 start-page: 5053 year: 2021 ident: ref_98 article-title: Value of Machine Learning with Multiphases CE-MRI Radiomics for Early Prediction of Pathological Complete Response to Neoadjuvant Therapy in HER2-Positive Invasive Breast Cancer publication-title: Cancer Manag. Res. doi: 10.2147/CMAR.S304547 contributor: fullname: Li – volume: 72 start-page: 146 year: 2021 ident: ref_77 article-title: PD-L1 status in breast cancer: Current view and perspectives publication-title: Semin. Cancer Biol. doi: 10.1016/j.semcancer.2019.12.003 contributor: fullname: Vranic – volume: 125 start-page: 7 year: 2021 ident: ref_195 article-title: Identifying patients eligible for PARP inhibitor treatment: From NGS-based tests to 3D functional assays publication-title: Br. J. Cancer doi: 10.1038/s41416-021-01295-z contributor: fullname: Morice – volume: 63 start-page: 691 year: 2017 ident: ref_144 article-title: Patient-Specific Circulating Tumor DNA Detection during Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer publication-title: Clin. Chem. doi: 10.1373/clinchem.2016.262337 contributor: fullname: Riva – volume: 82 start-page: 3 year: 2021 ident: ref_36 article-title: Breast cancer heterogeneity through the lens of single-cell analysis and spatial pathologies publication-title: Semin. Cancer Biol. doi: 10.1016/j.semcancer.2021.07.010 contributor: fullname: Zhao – volume: 11 start-page: 3782 year: 2020 ident: ref_117 article-title: Quantitative ultrasound radiomics using texture derivatives in prediction of treatment response to neo-adjuvant chemotherapy for locally advanced breast cancer publication-title: Oncotarget doi: 10.18632/oncotarget.27742 contributor: fullname: Dasgupta – volume: 13 start-page: 1714 year: 2022 ident: ref_39 article-title: A single-cell analysis of breast cancer cell lines to study tumour heterogeneity and drug response publication-title: Nat. Commun. doi: 10.1038/s41467-022-29358-6 contributor: fullname: Gambardella – volume: 25 start-page: 339 year: 2014 ident: ref_177 article-title: Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: Using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone publication-title: Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. doi: 10.1093/annonc/mdt494 contributor: fullname: Gnant – volume: 22 start-page: 1441 year: 2015 ident: ref_12 article-title: Pathological complete response in neoadjuvant treatment of breast cancer publication-title: Ann. Surg. Oncol. doi: 10.1245/s10434-015-4404-8 contributor: fullname: Cortazar – volume: 22 start-page: 2583 year: 2016 ident: ref_154 article-title: Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer publication-title: Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. doi: 10.1158/1078-0432.CCR-15-1603 contributor: fullname: Janni – volume: 22 start-page: 5747 year: 2016 ident: ref_67 article-title: Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer publication-title: Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. doi: 10.1158/1078-0432.CCR-15-2338 contributor: fullname: Untch – volume: 12 start-page: 1354 year: 2021 ident: ref_100 article-title: MRI texture features from tumor core and margin in the prediction of response to neoadjuvant chemotherapy in patients with locally advanced breast cancer publication-title: Oncotarget doi: 10.18632/oncotarget.28002 contributor: fullname: Kolios – volume: 33 start-page: 109 year: 2018 ident: ref_53 article-title: Apoptosis regulator Bcl-2 is an independent prognostic marker for worse overall survival in triple-negative breast cancer patients publication-title: Int. J. Biol. Markers doi: 10.5301/ijbm.5000291 contributor: fullname: Ozretic – ident: ref_135 doi: 10.3390/cancers13081964 – ident: ref_182 doi: 10.1186/s12916-015-0540-z |
SSID | ssj0000331767 |
Score | 2.4835935 |
SecondaryResourceType | review_article |
Snippet | Pathological complete response (pCR) after neoadjuvant chemotherapy in patients with early breast cancer is correlated with better survival. Meanwhile, an... Despite the increased use of neoadjuvant chemotherapy in the early setting of breast cancer, there is a clinical need for predictive markers of response in... Simple SummaryDespite the increased use of neoadjuvant chemotherapy in the early setting of breast cancer, there is a clinical need for predictive markers of... |
SourceID | pubmedcentral proquest gale crossref |
SourceType | Open Access Repository Aggregation Database |
StartPage | 3876 |
SubjectTerms | Biological markers Biomarkers Biopsy Breast cancer Cancer Cancer therapies Chemotherapy Classification Clinical decision making Clinical medicine Cloning Decision making Gene expression Health aspects Hypotheses Hypoxia Lymphatic system Medical prognosis Metastasis Methods Microenvironments Neoadjuvant therapy Patients Precision medicine Predictions Review Surgery Tumors |
SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1La9wwEBZtAqWX0kdK3KZBhUByMVnrafVSsiFLKGRZQgO5GethsoHaqe095A_kd3fGq91k99CbsWQsNNI8pG--IeSIm8xIHUSaWSxhxkKVwipxaeaFsN46xSvMHb6aqssb8etW3sYDty7CKlc6cVDUvnF4Rn7K9GCMIWL7-fA3xapReLsaS2i8JrssE3hNuzu-mM6u16csIw72Ueklpw-H-P7U4WS2XTY4Isg08sIcbSvlbaDkC8szeU_eRZeRni1l_IG8CvVH8uYqXop_Ik-zFp9Rb9HxvPmDgJu2o01Fr5cA2ED7hk5DU_r7BTjOPUWWgJh59UjnNR0jMh1eD4P-QSNnEy1rTycD5widPedkdhT8XDprY3EeuhrIHrmZXPw-v0xjeYXUCSX7NMM66EzkzvgS4hTvK40JWFIGHkpprdZWSZ97a0XJZW7yYMrKSBZy5f0o1_wz2ambOuwT6sDCcV1Zy3zAZNcyKCN5JSrlbT5iJiEnq1kuHpYsGgVEHyiQYksgCTlGKRS4v2DOXRnTBOBHyFRVnGkGPhSHuDUhBxs9YV-4zeaVHIu4L7vieRUl5Pu6Gb9ErFkdmsXQRyuEXsqE6A35r8eOnNybLfX8buDmNuAAQ4j25f8__0reMkyjGICEB2SnbxfhGzg3vT2MK_gfjZj-uA priority: 102 providerName: ProQuest – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1ta9RAEF60gvhF6htGq6wg6JfoZd9XEGnFowhXDvGg30I2u8GTNtFcDuwf6O92Zm-vNUfxW8hukmFmdvcZMvMMIa-5LazUQeSFwxZmLDQ5eEmdF14I512teIO1w7MTdbwQX0_l6XU7oKTA1Y2hHfaTWvRn7_78vvgEC_4jRpwQsr-vUT_9qojYQqvb5A4TXKC7zxLWj9syh6MydpRlE81ypazYUP3c9I7RKbW7V-_mT_5zIE33yf2EJOnhxvQPyK3QPiR3Z-lf-SNyOe_xGrczerTszjEPp1_RrqHfNnmxgQ4dPQld5X-uAU8PFMkDUkHWBV229AgT1uF2FPoDTVROtGo9nUYqEjq_LtVcUYC_dN6nnj10K8hjsph--f75OE9dF_JaKDnkBbZHZ8LU1lcQvnjfaKzLkjLwUEnntHZKeuOdExWXxppgq8ZKFozyfmI0f0L22q4NTwmt4eDjunGO-YA1sFVQVvJGNMo7M2E2I2-3Wi5_bcg1SghK0CDljkEy8gatUKIjgM7rKlUPwIeQwKo81GBzwKJFkZGD0UxYLvV4eGvHcuttJdMR6WljMvLqahifxBS0NnTrOEcrzMiUGdEj-1_JjlTd45F2-SNSdlvAxRC5Pfu_bM_JPYbVFTG_8IDsDf06vADMM7iX0Zf_Ap9TAtc priority: 102 providerName: Scholars Portal |
Title | Predictive Biomarkers of Response to Neoadjuvant Chemotherapy in Breast Cancer: Current and Future Perspectives for Precision Medicine |
URI | https://www.proquest.com/docview/2706125788 https://search.proquest.com/docview/2707610805 https://pubmed.ncbi.nlm.nih.gov/PMC9405974 |
Volume | 14 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9tAEB7iFEovpU-qNjVbKLQXxZF2Vyv1Foe4oWAjQgO-Ce1D1KWWgiwf-gf6uzuzllLbx16E0K7QsDO78w36ZgbgI8-iTConwkhTC7PYVSFaiQkjK4S22iS8otzh-SK5uRPflnJ5AnLIhfGkfaNX5_Wv9Xm9-uG5lfdrMxl4YpN8fpUhykAcPBnBSHG-F6L745ejS0zUrowPx5B-Ymj92k3ksYeipkWcwpCUSM57zuj4SD6mSe75ndkzeNoDRna5E-w5nLj6BTye97_EX8KfvKV7OrXYdNWsiW7TblhTsdsd_dWxrmEL15T25xZhc8eoRkCfd_WbrWo2JV46Pvbyf2F9xSZW1pbNfMURlv_LyNwwRLksb_vWPGwQ5BXcza6_X92EfXOF0IhEdmFEXdBjkZrMlhilWFspSr-S0nFXSq2V0om0qdValFymWeqysspk7NLE2otU8ddwWje1ewPMoH_jqtI6to5SXUuXZJJXokqsTi_iLIDPwyoX97saGgXGHqSb4kg3AXwiLRS0u3DNTdknCeCHqE5VcaliRFAco9YAzg5m4q4wh8ODHot-V26KWHlAh1F_AB8ehulNYprVrtn6OSoh4qUMQB3o_0F2qsh9OIKG6itz94b59r_ffAdPYsqv8AzDMzjt2q17j6in02N4NL1e5LdjGH1dRnidi3TsLf8vPOEJxg |
link.rule.ids | 230,315,733,786,790,891,2236,21416,24346,27955,27956,33777,33778,43838,53825,53827,74657 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3Nb9MwFH-CToJdJj5F2AAjIcElWhPHdswFrWhVgbWqpk3aLYpjR3TSki1JD_wD_N28l7rd2gO3KHYUy89-H_bv_R7AJ64jLZRLwshQCbPYlSGukiKMbJIYawrJS8odns7k5DL5eSWu_IFb62GVa53YK2pbF3RGfhyr3hhjxPbt9i6kqlF0u-pLaDyGPaLcTAewNzqdzc83pyxDjvZRqhWnD8f4_rigyWzaqHdEiGnkgTnaVcq7QMkHlmf8DA68y8hOVjJ-Do9c9QKeTP2l-Ev4O2_omfQWGy3qGwLcNC2rS3a-AsA61tVs5urcXi_Rce4YsQT4zKs_bFGxESHT8XU_6K_MczaxvLJs3HOOsPl9TmbL0M9l88YX52HrgbyCy_HpxfdJ6MsrhEUiRRdGVAc9TtJC2xzjFGtLRQlYQjjucmGMUkYKm1pjkpyLVKdO56UWsUultcNU8dcwqOrKvQFWoIXjqjQmto6SXXMnteBlUkpr0mGsA_iynuXsdsWikWH0QQLJdgQSwGeSQkb7C-e8yH2aAP6ImKqyExWjD8Uxbg3gaKsn7otiu3ktx8zvyza7X0UBfNw005eENatcvez7KEnQSxGA2pL_ZuzEyb3dUi1-99zcGh1gDNHe_v_nH-Dp5GJ6lp39mP06hP2YUip6UOERDLpm6d6ho9OZ9341_wPAbgG9 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1La9wwEBZtAqGXkr6o2zxUKLQXs2vLkqxeSrbJkj6ymNBAbsZ6kS3UTm3vIX-gv7szXu0mu4fejCVjMSNpZqRvviHkPVOJ4tJlcaKxhFnqfAyzxMSJzTJttRHMY-7wxUycX2Xfrvl1wD91AVa52hOHjdo2Bs_IR6kcjDFEbCMfYBHF6fTz7Z8YK0jhTWsop_GY7MpMcAjEdidns-JyfeIyZmArhVzy-zCI9UcGBdt2yeCUIOvIA9O0vUFvgyYfWKHpPnka3Ed6stT3M_LI1c_J3kW4IH9B_hYtPuMeRifz5jeCb9qONp5eLsGwjvYNnbmmsr8W4ET3FBkDQhbWHZ3XdIIodXg9DPoTDfxNtKotnQ78I7S4z8_sKPi8tGhDoR66GshLcjU9-_nlPA6lFmIDsurjBGuip1lulK0gZrHWS0zG4twxV3GtpdSC29xqnVWM5yp3qvKKpy4X1o5zyV6Rnbqp3WtCDVg7Jr3WqXWY-Fo5oTjzmRdW5-NUReTjSsrl7ZJRo4RIBBVSbikkIh9QCyWuNZC5qULKAPwIWavKE5mCP8Ugho3IwUZPWCNms3mlxzKs0a68n1ERebduxi8Rd1a7ZjH0kQJhmDwickP_67EjP_dmSz2_GXi6FTjDEK69-f_Pj8keTOTyx9fZ97fkSYrZFQO-8IDs9O3CHYLP0-ujMJn_AYnCBfE |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Predictive+Biomarkers+of+Response+to+Neoadjuvant+Chemotherapy+in+Breast+Cancer%3A+Current+and+Future+Perspectives+for+Precision+Medicine&rft.jtitle=Cancers&rft.au=Derouane%2C+Fran%C3%A7oise&rft.au=van+Marcke%2C+C%C3%A9dric&rft.au=Berli%C3%A8re%2C+Martine&rft.au=Gerday%2C+Amandine&rft.date=2022-08-01&rft.pub=MDPI+AG&rft.issn=2072-6694&rft.eissn=2072-6694&rft.volume=14&rft.issue=16&rft_id=info:doi/10.3390%2Fcancers14163876&rft.externalDocID=A724393211 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2072-6694&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2072-6694&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2072-6694&client=summon |